Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
L CastagnaVittorio Montefusco

Abstract

Allogeneic (allo) hematopoietic cell transplantation (HCT) currently represents the only potentially curative therapy for patients affected by multiple myeloma (MM). Up to 30% of patients in western countries do not have a matched donor. Haploidentical HCT (haplo-HCT) may be an option, but currently, there are little available data regarding this treatment. We analyzed survival outcomes of 30 heavily pretreated MM patients who received haplo-HCT with post-transplantation cyclophosphamide as graft-versus-host-disease (GVHD) prophylaxis. Median neutrophil and platelet engraftments at day +30 were 87% (95% confidence interval [CI], 66% to 95%) and 60% (95% CI, 40% to 75%), respectively. The cumulative incidences of relapse or progression of disease (PD) and nonrelapse mortality at 18 months were 42% (95% CI, 23% to 59%) and 10% (95% CI, 2% to 24%), respectively. The cumulative incidence of grade II to IV acute GVHD at day +100 was 29% (95% CI, 14% to 47%). The cumulative incidence of chronic GVHD at 18 months was 7% (95% CI, 1% to 21%). With a median follow-up in survivors of 25 months (range, 15 to 73 months), the 18-month progression-free survival (PFS) and overall survival (OS) were 33% (95% CI, 17% to 50%) and 63% (95% CI, 44%...Continue Reading

References

Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LokhorstL F Verdonck
Jan 10, 2001·Bone Marrow Transplantation·M SalamaR H Collins
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ashraf BadrosGuido Tricot
Sep 25, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicolaus KrögerAxel Rolf Zander
Feb 26, 2008·Bone Marrow Transplantation·H de LavalladeM Mohty
May 21, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Leo LuznikEphraim J Fuchs
Nov 21, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yvette L KasamonEphraim J Fuchs
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Francesca PatriarcaPaolo Corradini
Nov 3, 2011·Bone Marrow Research·Salem AlshemmariJavid Gaziev
Mar 15, 2013·Bone Marrow Transplantation·Simona Iacobelli, UNKNOWN EBMT Statistical Committee
Mar 14, 2013·Blood·Gösta GahrtonUNKNOWN EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee
Dec 3, 2014·The Lancet Oncology·S Vincent RajkumarJesus F San Miguel
Dec 23, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Madan H JagasiaMary E D Flowers
Feb 5, 2015·Transplant Infectious Disease : an Official Journal of the Transplantation Society·R CrocchioloL Castagna
Aug 12, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yvette L KasamonRichard J Jones
Sep 12, 2015·Transplant Infectious Disease : an Official Journal of the Transplantation Society·A RuggeriM Mohty
Jan 5, 2016·Bone Marrow Transplantation·B DhakalP N Hari

❮ Previous
Next ❯

Citations

Mar 2, 2018·Expert Review of Hematology·Yu-Qian SunXiao-Jun Huang
Jan 14, 2018·Bone Marrow Transplantation·Yao ChenXiao-Jun Huang
Jul 16, 2020·Journal of Clinical Medicine·Gösta GahrtonStefan Schönland
Jan 13, 2018·Frontiers in Oncology·Ehsan MalekMarcos de Lima
Nov 23, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sergio GiraltEdward Stadtmauer
Jul 28, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra Gomez-ArteagaDavid J Chung
Oct 30, 2020·Journal of Clinical Medicine·Alberto MussettiVittorio Montefusco
Mar 3, 2021·Journal of Korean Medical Science·Jongheon JungEunyoung Lee
Mar 7, 2021·Cancers·Srinivas DevarakondaNidhi Sharma
Sep 24, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Firoozeh SahebiParameswaran Hari
Mar 7, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Saurabh ChhabraParameswaran N Hari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Junichi SugitaJapan Study Group for Cell Therapy and Transplantation
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Nicoletta CieriJacopo Peccatori
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Melissa BakerMichele L Donato
© 2022 Meta ULC. All rights reserved